Opko Health Inc (NYSE:OPK) stock is expected to deviate a maximum of $4.27 from the average target price of $15.25 for the short term period. 4 Street Experts have initiated coverage on the stock with the most promising target being $20 and the most muted being $10.
Other Equity analysts have also commented on the company shares. Deutsche Bank maintains its rating on Opko Health Inc (NYSE:OPK). The global brokerage major lowers the current price target from $11 per share to $10 per share. Analysts at the Deutsche Bank have a current rating of Hold on the shares. The rating by the firm was issued on June 16, 2016.
Opko Health Inc (NYSE:OPK): stock turned positive on Thursday. Though the stock opened at $9.52, the bulls momentum made the stock top out at $9.75 level for the day. The stock recorded a low of $9.46 and closed the trading day at $9.75, in the green by 4.17%. The total traded volume for the day was 3,149,880. The stock had closed at $9.36 in the previous days trading.
The company shares have dropped -39.26% from its 1 Year high price. On Jul 24, 2015, the shares registered one year high at $17.51 and the one year low was seen on Jan 20, 2016. The 50-Day Moving Average price is $9.87 and the 200 Day Moving Average price is recorded at $9.75. On the companys insider trading activities, Frost Gamma Investments Trust, CEO of Opko Health, Inc., executed a transaction worth $92,400 on June 16, 2016. A total of 10,000 shares were purchased at an average price of $9.24. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
OPKO Health, Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile, Spain, Mexico, Israel, Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.